news
Anti-PD-1 autoantibody: a biomarker candidate for HCC
The researchers discovered that anti-PD-1 autoantibodies influence the outcome of Atezo/Bev therapy for hepatocellular carcinoma.
List view / Grid view
Antibodies
news
New monoclonal antibody drug could combat antimicrobial resistance
Scientists have developed a monoclonal antibody drug that could help to prevent infection from Acinetobacter baumannii.
news
Sino Biological and BioGeometry: advancing protein R&D
The expansion of Sino Biological and BioGeometry’s strategic partnership promises to accelerate drug discovery.
article
A novel class of drug candidates for neurodegenerative diseases
At AAIC 2024, AC Immune unveiled a new class of antibody drug conjugates, called morADC (Morphomer® antibody drug conjugate). In this Q&A, CEO of AC Immune, Andrea Pfeifer, discusses how morADC uses the capabilities of the company’s two discovery platforms to combine two highly selective molecules, resulting in drug candidates…
article
Rapid delivery of toxicological material
With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the provision of toxicology data to support INDs for new therapeutics and hence delivery of FIH studies, explains Alejandro Fernandez Martell and James Berrie from Lonza.
news
mRNA vaccine provides enhanced protection against mpox
The mRNA vaccine candidate more effectively limited symptoms and disease duration in non-human primates.
news
Pancreatic cancer suppressed by humanised anti-CKAP4 antibody
The humanised antibody, Hv1Lt1, showed promising results in pancreatic cancer mouse models.
podcasts
Combatting disease with antibody drug conjugates
Tune into this episode where we investigate how antibody drug conjugates can be optimised, as well as the future of the field.
article
Exploring the potential of ADCs beyond oncology
Antibody Drug Conjugates (ADCs) are already deployed as part of the roster of oncology treatments, but here, Mike Ward, Head of Thought Leadership for Life Sciences & Healthcare, Clarivate, looks into their potential to help treat a whole range of other diseases and conditions. He discusses the barriers and enablers…
news
Reprogramming B cells to produce custom antibodies
The new technique could be adapted to produce a wide range of antibodies to combat chronic conditions like HIV.
article
Supercharging conventional monoclonal antibodies
In this Q&A, Krishna Polu and Dennis Pedersen, senior leaders of Commit Biologics, which is backed by Novo Holdings and Bioqube Ventures, elucidate how their technology differs from other existing therapeutic platforms and highlight its implications for the treatment of both cancer and autoimmune disease.
article
Unleashing the potential of lab-grown recombinant polyclonal antibodies
In this Q&A, Sheila Keating, Vice President of Immunology at GigaGen, a Grifols company, explains how its developments in recombinant polyclonal antibody therapies are helping to build a pipeline of highly effective treatments for a wide range of diseases, including the hepatitis B virus.
article
Leveraging ADCs in precision oncology strategy
In this Q&A, senior leaders at Caris Life Sciences discuss how the company is advancing precision medicine by integrating ADCs into patient-specific cancer treatment plans, focusing on novel target discovery through comprehensive molecular profiling and clinico-genomic data.
news
New study challenges assumptions about the development of RA
Scientists have discovered that each rheumatoid arthritis patient possesses a unique and diverse set of ACPAs.
news
Improved method to control the generation of dopaminergic neurons
A synthetic antibody selectively activates the Wnt signalling pathway and directs stem cells to differentiate into neurons.